Literature DB >> 15750669

[HALS: HIV-Lipodystrophy associated syndrome].

S Hilton1, S Mauss, T Ruzicka, D Bruch-Gerharz.   

Abstract

Entities:  

Mesh:

Year:  2005        PMID: 15750669     DOI: 10.1007/s00105-005-0925-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


× No keyword cloud information.
  6 in total

1.  Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone.

Authors:  S Mauss; E Wolf; H Jaeger
Journal:  Ann Intern Med       Date:  1999-08-17       Impact factor: 25.391

2.  Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy.

Authors:  T Saint-Marc; J L Touraine
Journal:  AIDS       Date:  1999-05-28       Impact factor: 4.177

Review 3.  Fat distribution and metabolic changes in patients with HIV infection.

Authors:  S Safrin; C Grunfeld
Journal:  AIDS       Date:  1999-12-24       Impact factor: 4.177

4.  Use of ultrasonography-assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad.

Authors:  P J Piliero; M Hubbard; J King; J J Faragon
Journal:  Clin Infect Dis       Date:  2003-10-13       Impact factor: 9.079

Review 5.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Authors:  A Carr; K Samaras; D J Chisholm; D A Cooper
Journal:  Lancet       Date:  1998-06-20       Impact factor: 79.321

6.  Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.

Authors:  Marc-Antoine Valantin; Camille Aubron-Olivier; Jade Ghosn; Elisabeth Laglenne; Michelle Pauchard; Hélène Schoen; Raymond Bousquet; Philippe Katz; Dominique Costagliola; Christine Katlama
Journal:  AIDS       Date:  2003-11-21       Impact factor: 4.177

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.